Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial
Authors' conclusion
Colchicine and prednisone exhibit equivalent short-term efficacy for the treatment of acute calcium pyrophosphate crystal arthritis, with different safety profiles in the older population.
Study context
- Population
- Hospitalised patients aged 65 years or older with acute CPP crystal arthritis, symptom duration <36 h; six hospitals in Paris and northern France95 per-protocol
- Participants
- 111 patients
- Comparison
- Low-dose colchicine vs oral prednisone
- Colchicinen = 57
- Prednisonen = 54reference
- Primary endpoint
- Change in joint pain (VAS 0–100 mm)
- Follow-up
- 24 h
Methodological detailsopen-label, multicentre, equivalence
- Open-label
- Multicentre
- Equivalence
Primary result
As reported in the abstract
Colchicine
−36
SD 32 · mm
Prednisone
−38
SD 23 · mm
Further findings
Events
| Outcome | Colchicine | Prednisone |
|---|---|---|
| DeathsDeemed unrelated to prednisone | 0 | 2 |
Safety
Diarrhoea
Hypertension
| Outcome | Colchicine | Prednisone |
|---|---|---|
| Hyperglycaemia | 0 events | 6% |
- Diarrhoea: denominators 55 and 54
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. Lancet Rheumatol. Published 8 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →